MYD88 and B-cell non-Hodgkin lymphoma: In the field of oncology research, adverse effects from TLR immunotherapy have been linked to unintended expansion of adaptive leukocytes, such in B-cell lymphoma, where activation of TLR4 MyD88-dependent signaling may exacerbate the disease (258–260).